Source: World Health Organization
Resolution WHA67.6 requested the Director-General to assist Member States in ensuring equitable access to quality, effective, affordable and safe HCV treatments. For governments to identify ways of increasing access and affordability to these treatments, clarity about whether the medicines are patent protected in the respective countries is needed. Assessing the patent situation requires expert knowledge and access to specialized databases. Therefore, to assist countries in this endeavor, the WHO Secretariat has mandated Thomson Reuters to carry out an analysis of the patent situation of seven new hepatitis treatments.
The working papers can be accessed here